Wall Street Rallies as Fed’s Waller Hints at September Rate Hold: Stock Market Today
Stocks rallied and Treasury yields retreated from three-year highs after Fed Governor Waller signaled he could back a rate hold, sending bitcoin above $80,000.
Stocks · News reference
Summit Therapeutics' Partner Akeso Announces Overall Survival Results From The Randomized, Double-Blind Phase III HARMONi-2 Study Evaluating Ivonescimab Monotherapy; Ivonescimab Monotherapy Demonstrated A Statistically Significant Improvement Compared To Pembrolizumab Monotherapy.
Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study
Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in a Phase 3 lung cancer clinical trial.
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake and other stocks rallied.
8-K filing — Summit Therapeutics Inc. (SMMT)
Filed: 2026-09-03 AccNo: 0001599298-26-000076 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits